Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT

Blood. 2007 Jun 1;109(11):5058-61. doi: 10.1182/blood-2007-01-065383. Epub 2007 Feb 22.

Abstract

Natural killer (NK) cells can alter the outcome of hematopoietic cell transplantation (HCT) if donor alloreactivity targets the recipient. Since most NK cells express inhibitory killer-immunoglobulin receptors (KIRs), we hypothesized that the susceptibility of recipient cells to donor NK cell-mediated lysis is genetically predetermined by the absence of known KIR ligands. We analyzed data from 2062 patients undergoing unrelated donor HCT for acute myeloid leukemia (AML; n = 556), chronic myeloid leukemia (CML; n = 1224), and myelodysplastic syndrome (MDS; n = 282). Missing 1 or more KIR ligands versus the presence of all ligands protected against relapse in patients with early myeloid leukemia (relative risk [RR] = 0.54; n = 536, 95% confidence interval [CI] 0.30-0.95, P = .03). In the subset of CML patients that received a transplant beyond 1 year from diagnosis (n = 479), missing a KIR ligand independently predicted a greater risk of developing grade 3-4 acute graft-versus-host disease (GVHD; RR = 1.58, 95% CI 1.13-2.22; P = .008). These data support a genetically determined role for NK cells following unrelated HCT in myeloid leukemia.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Genetic Predisposition to Disease
  • Graft vs Host Disease / diagnosis*
  • Graft vs Host Disease / metabolism*
  • Humans
  • Killer Cells, Natural / cytology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / blood
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myeloid, Acute / blood
  • Leukemia, Myeloid, Acute / immunology
  • Ligands
  • Myelodysplastic Syndromes / blood
  • Myelodysplastic Syndromes / immunology
  • Receptors, Immunologic / chemistry
  • Receptors, Immunologic / immunology*
  • Receptors, KIR
  • Recurrence
  • Registries
  • Risk
  • Transplantation, Homologous / methods*
  • Treatment Outcome

Substances

  • Ligands
  • Receptors, Immunologic
  • Receptors, KIR